Username Password
S&P 500: 1,988.87
Change: +0.06%

MYLAN INC (MYL)

Overview
Price 50.37
Price Change Today -$1.12 (-2.18%)
P&P rating Rating: 3
Open Price $51.63
Previous Close $51.49
Daily Range $49.82 - $51.93
52-Week Range $44.80 - $76.69
Volume 7
chart
Top Buy Analysis
BUY: MYL Rating: 3
Company: MYLAN INC
Points: 69.47
Start Price: $23.24
Start Date: 02/14/2012 12:19 PM
BlackMac
BlackMac
P&P Score: 91.32
Recs:
Mylan has a low beta .87 and a five-year projected PEG of under 1. It also sells for just 9 times forward earnings. Its gaining technical strength as it passed its 200-day moving average

Comments: 0 | Comment

Top Sell Analysis
SELL: MYL Rating: 3
Company: MYLAN INC
Points: -100.36
Start Price: $17.98
Start Date: 11/23/2009 1:51 PM
francjohn
francjohn
P&P Score: 70.12
Recs:
once the FY09 results come out, it should be at $20 which is a good enough run back up for this stock

Comments: 0 | Comment

Rate this Stock!
You haven't rated this stock yet!

What The Community Thinks

Total Players

26 Buy
2 Sell
 
Blog Posts
User User Score Date Title Comments Last Comment
rjm77me
99.96 04/09/14 What is better - back test your own closed trades or hypothetical Trades 2 04/09/14
rjm77me
99.96 04/05/14 Is Market Rigged = If your are a smart trader then follow the smart money 10 04/10/14
rjm77me
99.96 02/26/10 100% profits in 6 weeks and sleep like a baby 9 03/07/10
rjm77me
99.96 02/25/10 MYL - Break out above 52 week high Personal Buy 3 03/18/10
Zacks_Analysts
0.00 02/15/13 Dr. Reddy's Misses on Both Counts - Analyst Blog 0
Zacks_Analysts
0.00 02/15/13 Dr. Reddy's Misses on Both Counts - Analyst Blog 0
Zacks_Analysts
0.00 02/14/13 Mylan Extends Biocon Collaboration - Analyst Blog 0
Zacks_Analysts
0.00 02/14/13 Mylan Extends Biocon Collaboration - Analyst Blog 0
Zacks_Analysts
0.00 02/12/13 Teva Enrolls First Patient in Study - Analyst Blog 0
Zacks_Analysts
0.00 02/12/13 Teva Enrolls First Patient in Study - Analyst Blog 0
Pages: [ 1 ]  2   3   4   5   ...  29  >>
Commentary
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $21.00
Points: +94.59
Created: 05/03/2012
Attractive earnings yield, cost advantage vs. big Pharma

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $21.00
Points: +86.11
Created: 05/03/2012
Attractive earnings yield, cost advantage vs. big Pharma

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $21.00
Points: +85.89
Created: 05/03/2012
Attractive earnings yield, cost advantage vs. big Pharma

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $21.00
Points: +94.59
Created: 05/03/2012
Attractive earnings yield, cost advantage vs. big Pharma

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $21.00
Points: +86.11
Created: 05/03/2012
Attractive earnings yield, cost advantage vs. big Pharma

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $21.00
Points: +85.89
Created: 05/03/2012
Attractive earnings yield, cost advantage vs. big Pharma

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $23.24
Points: +69.47
Created: 02/14/2012
Mylan has a low beta .87 and a five-year projected PEG of under 1. It also sells for just 9 times forward earnings. Its gaining technical strength as it passed its 200-day moving average

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $23.24
Points: +60.87
Created: 02/14/2012
Mylan has a low beta .87 and a five-year projected PEG of under 1. It also sells for just 9 times forward earnings. Its gaining technical strength as it passed its 200-day moving average

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $23.24
Points: +60.65
Created: 02/14/2012
Mylan has a low beta .87 and a five-year projected PEG of under 1. It also sells for just 9 times forward earnings. Its gaining technical strength as it passed its 200-day moving average

Comments: 0 | Comment

Recs:
 
BUY: MYLAN INC (MYL) Rating: 3
Start Price: $23.24
Points: +69.47
Created: 02/14/2012
Mylan has a low beta .87 and a five-year projected PEG of under 1. It also sells for just 9 times forward earnings. Its gaining technical strength as it passed its 200-day moving average

Comments: 0 | Comment

Recs:
 
Pages: [ 1 ]  2   3  >>
Picks
Username P&P Score Call Time Frame Start Date Start Price Today (change) Stock Gain S&P Gain Points Analysis
hutton2 0.24 BUY One to Three Months 01/05/2015 $55.72 $50.37
(-2.18%)
-9.60% -1.57% -8.03
hutton2 0.24 BUY One to Three Months 01/05/2015 $55.72 $50.37
(-2.18%)
-9.60% +4.18% -13.78
hutton2 0.24 BUY One to Three Months 01/05/2015 $55.72 $50.37
(-2.18%)
-9.60% +4.32% -13.93
hutton2 0.24 BUY One to Three Months 01/05/2015 $55.72 $50.37
(-2.18%)
-9.60% -1.57% -8.03
hutton2 0.24 BUY One to Three Months 01/05/2015 $55.72 $50.37
(-2.18%)
-9.60% +4.18% -13.78
hutton2 0.24 BUY One to Three Months 01/05/2015 $55.72 $50.37
(-2.18%)
-9.60% +4.32% -13.93
jbaxter228 60.66 BUY One to Three Years 05/03/2012 $21.00 $50.37
(-2.18%)
+139.86% +45.27% +94.59 view
jbaxter228 60.66 BUY One to Three Years 05/03/2012 $21.00 $50.37
(-2.18%)
+139.86% +53.75% +86.11 view
jbaxter228 60.66 BUY One to Three Years 05/03/2012 $21.00 $50.37
(-2.18%)
+139.86% +53.97% +85.89 view
jbaxter228 60.66 BUY One to Three Years 05/03/2012 $21.00 $50.37
(-2.18%)
+139.86% +45.27% +94.59 view
Pages: [ 1 ]  2   3  >>
Sponsored Links